CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Neurology

• Publication date

  2010-09-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/WNL.0b013e3181f39a78PMID 20720189PMCID PMC2942062
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Progression from MCI to AD: predictive value of CSF Aβ42 is modified by APOE genotype.

  2011cited by this paper
• Random Effects Models for Longitudinal Data

  2010cited by this paper
• CSF biomarkers predict rate of cognitive decline in Alzheimer disease

  2009cited by this paper
• Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

  2009cited by this paper
• Neurochemical biomarkers in the differential diagnosis of movement disorders

  2009cited by this paper
• Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort

  2009cited by this paper
• Cerebrospinal tau, phospho‐tau, and beta‐amyloid and neuropsychological functions in Parkinson's disease

  2009cited by this paper
• Association of plasma amyloid β with risk of dementia

  2009cited by this paper
• The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort.

  2009cited by this paper
• Dementia and survival in Parkinson disease

  2008cited by this paper
• Cut‐off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease

  2008cited by this paper
• Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics

  2007cited by this paper
• Clinical diagnostic criteria for dementia associated with Parkinson's disease

  2007cited by this paper
• DLB and PDD boundary issues

  2007cited by this paper
• Cerebrospinal fluid β-amyloid 1–42 concentration may predict cognitive decline in older women

  2006cited by this paper
• Apolipoprotein E and dementia in Parkinson disease: a meta-analysis.

  2006cited by this paper
• CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

  2006cited by this paper
• Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease

  2006cited by this paper
• Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

  2005cited by this paper
• Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer’s disease

  2005cited by this paper
• Diagnosis and management of dementia with Lewy bodies

  2005cited by this paper
• APOE ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42

  2004cited by this paper
• APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42.

  2004cited by this paper
• Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

  2003cited by this paper
• Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

  2003cited by this paper
• Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.

  2001cited by this paper
• Mental symptoms in Parkinson's disease are important contributors to caregiver distress

  1999cited by this paper
• Validity of the Dementia Rating Scale in Assessing Cognitive Function in Parkinson's Disease

  1999cited by this paper
• CSF beta-amyloid, cognition, and APOE genotype in Alzheimer’s disease

  1999cited by this paper
• Differential contributions of cognitive and motor component processes to physical and instrumental activities of daily living in Parkinson's disease.

  1998cited by this paper
• High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

  1998cited by this paper
• [Dementia rating scale].

  1997cited by this paper
• Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

  1995cited by this paper
• Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease

  1995cited by this paper
• Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

  1993cited by this paper
• Antecedent clinical features associated with dementia in Parkinson's disease

  1993cited by this paper
• The clinical features of Parkinson's disease in 100 histologically proven cases.

  1993cited by this paper
• Random-effects models for longitudinal data.

  1982cited by this paper
• Parkinsonism

  1967cited by this paper

• Clinical and Biological Determinants of Longitudinal Cognitive Function in Patients With GBA1 Variants and Subthalamic Deep Brain Stimulation.

  2026cites this paper
• Predicting Cognition and Affective Changes in Newly Diagnosed Parkinson's Disease Through Longitudinal Data-Driven Clustering.

  2025cites this paper
• Biomarkers in Parkinson's Disease.

  2025cites this paper
• Refutation of the αSyn‐SAA‐Based Staging for Parkinson's Progression (Neuronal α‐Synuclein Disease‐Integrated Staging System [NSD‐ISS])

  2025cites this paper
• Managing cognitive impairment in Parkinson’s disease: an update of the literature

  2025cites this paper
• Olfactory dysfunction and amyloid-positivity in Parkinson’s disease—longitudinal analysis of cognitive decline and cerebrospinal fluid markers

  2025cites this paper
• A lightweight cerebrospinal fluid biomarker-based model for first-diagnosis prediction of Parkinson’s disease: model development, external validation, and local deployment

  2025cites this paper
• Relationship of cognitive decline with glucocerebrosidase activity and amyloid‐beta 42 in DLB and PD

  2025cites this paper
• Diagnostic and prognostic value of α-synuclein seed amplification assay kinetic measures in Parkinson's disease: a longitudinal cohort study.

  2025cites this paper
• Non-Motor Symptoms: The Hidden Face of Parkinson’s Disease

  2025cites this paper
• Where do PDD and DLB SYNdromes fit in neuronal alpha-SYNuclein biological frameworks?

  2025cites this paper
• A splice‐switching antisense oligonucleotide targeting APP reduces accumulation of α‐synuclein in a mouse model of Parkinson's disease

  2025cites this paper
• Microbiome and metabolome integrated analysis: exploring potential diagnostic approaches for Parkinson’s disease using tongue coating samples

  2025influential citation
• Utility of Baseline Pathological, Neuroimaging and Clinical Markers for Prognosis in Early Parkinson's Disease.

  2025cites this paper
• Non-motor Symptoms and Treatments in Parkinson's Disease.

  2025cites this paper
• Alzheimer's disease traits in Parkinson's disease without α‐synuclein seeding

  2025cites this paper
• CSF Biomarker‐Based Cognitive Trajectories in Parkinson's Disease‐Subjective Cognitive Decline

  2025cites this paper
• Age-related trends in amyloid positivity in Parkinson’s disease without dementia

  2025cites this paper
• A hypothesis explaining Alzheimer's disease, Parkinson's disease, and dementia with Lewy bodies overlap

  2025cites this paper
• Radionuclide Imaging of the Neuroanatomical and Neurochemical Substrate of Cognitive Decline in Parkinson’s Disease

  2024cites this paper
• Posterior hippocampal sparing in Lewy body disorders with Alzheimer’s copathology: An in vivo MRI study

  2024cites this paper
• Evaluation of ATNPD Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease

  2024cites this paper
• Unraveling the interplay of β-amyloid pathology and Parkinson's disease progression: Insights from autopsy-confirmed patients

  2024cites this paper
• The effect of Amyloid and Tau Co-pathology on disease progression in Lewy body dementia: A systematic review.

  2024cites this paper
• Cerebrospinal fluid glial fibrillary acidic protein, in contrast to amyloid beta protein, is associated with disease symptoms in Huntington's disease.

  2024cites this paper
• Alzheimer’s Disease Related Biomarkers Were Associated with Amnestic Cognitive Impairment in Parkinson’s Disease: A Cross-Sectional Cohort Study

  2024cites this paper
• Machine Learning for Early Detection of Cognitive Decline in Parkinson’s Disease Using Multimodal Biomarker and Clinical Data

  2024cites this paper
• Research advancement in fluid biomarkers for Parkinson’s disease

  2024cites this paper
• Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias.

  2024cites this paper
• Glypican-4 serum levels are associated with cognitive dysfunction and vascular risk factors in Parkinson’s disease

  2024cites this paper
• Anti-alpha synuclein and anti-tau immunotherapies: Can a cocktail approach work?

  2024cites this paper
• Retinal Alterations Predict Early Prodromal Signs of Neurodegenerative Disease

  2024cites this paper
• Single-molecule characterization of salivary protein aggregates from Parkinson’s disease patients: a pilot study

  2024cites this paper
• Risk factors and predictive models in the progression from MCI to Alzheimer's disease.

  2024cites this paper
• Continuing the search for fluid biomarkers to enhance Huntington's disease staging and therapeutic response.

  2024cites this paper
• Definition and diagnosis of Parkinson’s disease: guideline “Parkinson’s disease” of the German Society of Neurology

  2024cites this paper
• From Fundamental Amyloid Protein Self-Assembly to Development of Bioplastics

  2023cites this paper
• Fluid and tissue biomarkers in Parkinson's disease: Immunodetection or seed amplification? Central or peripheral?

  2023cites this paper
• Lysosomal Polygenic Burden Drives Cognitive Decline in Parkinson's Disease with Low Alzheimer Risk

  2023cites this paper
• Plasma glial fibrillary acidic protein as a biomarker of disease progression in Parkinson’s disease: a prospective cohort study

  2023cites this paper
• Serum neurofilament light chain levels in patients with cognitive deficits and movement disorders: comparison of cerebrospinal and serum neurofilament light chain levels with other biomarkers

  2023cites this paper
• Kinetic parameters of alpha-synuclein seed amplification assay correlate with cognitive impairment in patients with Lewy body disorders

  2023cites this paper
• Amyloid-beta and tau protein beyond Alzheimer’s disease

  2023cites this paper
• Cognitive Profile in Parkinson’s Disease Dementia Patients with Low versus Normal Cerebrospinal Fluid Amyloid Beta

  2023cites this paper
• The association of CSF biomarkers and cognitive decline with choroid plexus volume in early Parkinson's disease.

  2023cites this paper
• CSF biomarkers for predicting phenoconversion in patients with isolated REM sleep behaviour disorder.

  2023cites this paper
• Evolution and Predictive Role of Plasma Alzheimer's Disease-related Pathological Biomarkers in Parkinson's Disease.

  2023cites this paper
• Machine learning-based prediction of longitudinal cognitive decline in early Parkinson’s disease using multimodal features

  2023influential citation
• Parkinson’s disease therapy: what lies ahead?

  2023cites this paper
• Fluid and Biopsy Based Biomarkers in Parkinson’s Disease

  2023cites this paper
• The Mechanisms of the Roles of α-Synuclein, Amyloid-β, and Tau Protein in the Lewy Body Diseases: Pathogenesis, Early Detection, and Therapeutics

  2023cites this paper
• Basal Forebrain Atrophy, Cortical Thinning, and Amyloid‐β Status in Parkinson's disease‐Related Cognitive Decline

  2023cites this paper
• Altered sleep and neurovascular dysfunction in alpha-synucleinopathies: the perfect storm for glymphatic failure

  2023cites this paper
• CSF neurochemical profile and cognitive changes in Parkinson’s disease with mild cognitive impairment

  2023cites this paper
• How should we be using biomarkers in trials of disease modification in Parkinson’s disease?

  2023cites this paper
• Parkinson Disease Dementia Management: an Update of Current Evidence and Future Directions

  2023cites this paper
• Evaluation of ATNPD framework and biofluid markers to predict cognitive decline in early Parkinson's disease

  2023cites this paper
• Biomarkers in Parkinson’s Disease: A State of the Art Review

  2023cites this paper
• Sacades, pupils and blink tracking: More than meets the eye in the Parkinson's disease cognitive spectrum?

  2023cites this paper
• Altered BDNF levels are associated with cognitive impairment in Parkinson's disease patients with depression.

  2022cites this paper
• Path analysis of biomarkers for cognitive decline in early Parkinson’s disease

  2022cites this paper
• Clinical trajectories and biomarkers for weight variability in early Parkinson’s disease

  2022cites this paper
• Beta amyloid deposition and cognitive decline in Parkinson’s disease: a study of the PPMI cohort

  2022cites this paper
• Longitudinal striatal dopamine transporter binding and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in Parkinson’s disease

  2022cites this paper
• Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimer’s Disease to Parkinson’s Disease

  2022cites this paper
• The Role of Tau beyond Alzheimer’s Disease: A Narrative Review

  2022cites this paper
• Prediction and early biomarkers of cognitive decline in Parkinson disease and atypical parkinsonism: a population-based study

  2022cites this paper
• Neuropathological substrates of cognition in Parkinson's disease.

  2022cites this paper
• Plasma MIA, CRP, and Albumin Predict Cognitive Decline in Parkinson's Disease

  2022cites this paper
• REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson’s disease: a cross-sectional and longitudinal study

  2022cites this paper
• Quantifying regional α ‐synuclein, amyloid β, and tau accumulation in lewy body dementia

  2022cites this paper
• Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease

  2022cites this paper
• The associations of cerebrospinal fluid biomarkers with cognition, and rapid eye movement sleep behavior disorder in early Parkinson’s disease

  2022cites this paper
• Subjective Cognitive Complaints in Cognitively Normal Patients With Parkinson’s Disease: A Systematic Review

  2022cites this paper
• The epidemiology of cognitive function in Parkinson's disease.

  2022cites this paper
• Linking Stage-Specific Plasma Biomarkers to Gray Matter Atrophy in Parkinson Disease

  2021influential citation
• Cognitive Decline in Parkinson’s Disease: A Subgroup of Extreme Decliners Revealed by a Data-Driven Analysis of Longitudinal Progression

  2021cites this paper
• Progress regarding the context-of-use of tau as biomarker of Alzheimer’s disease and other neurodegenerative diseases

  2021cites this paper
• Amyloid-β: a potential link between epilepsy and cognitive decline

  2021cites this paper
• Repurposing GLP-1 Receptor Agonists for Parkinson’s Disease: Current Evidence and Future Opportunities

  2021cites this paper
• Arithmetic Errors in Financial Contexts in Parkinson’s Disease

  2021cites this paper
• Cognitive Profile and Markers of Alzheimer Disease–Type Pathology in Patients With Lewy Body Dementias

  2021cites this paper
• Cerebrospinal fluid neurofilament light predicts the rate of executive function decline in younger-onset dementia.

  2021cites this paper
• The dopamine receptor agonist apomorphine stabilizes neurotoxic α‐synuclein oligomers

  2021cites this paper
• Parkinsonism

  2021cites this paper
• Biomarker in Parkinson’s Disease: Clinical and Biochemical Biomarker

  2021cites this paper
• Are Parkinson’s Disease Patients the Ideal Preclinical Population for Alzheimer’s Disease Therapeutics?

  2021influential citation
• Low soluble amyloid-β 42 is associated with smaller brain volume in Parkinson's disease.

  2021cites this paper
• Cerebrospinal fluid amyloid beta and glial fibrillary acidic protein concentrations in Huntington’s disease

  2021cites this paper
• Temporal trajectory of biofluid markers in Parkinson’s disease

  2021cites this paper
• An Exploratory Study of Cognitive Involvement in Hereditary Transthyretin Amyloidosis

  2021cites this paper
• Association between Fatigue Level with Disease Severity in Myasthenia Gravis Patients

  2021cites this paper
• Lewy Body Dementias: A Coin with Two Sides?

  2021cites this paper
• Nonmotor problems in Parkinson disease

  2021cites this paper
• Parkinson disease-associated cognitive impairment

  2021cites this paper
• Is Parkinson's Disease the Ideal Preclinical Population for Alzheimer's Disease Therapeutics?

  2021influential citation
• Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases

  2020cites this paper
• Apolipoprotein E and Alzheimer’s disease: the influence of apolipoprotein E on amyloid-  and other amyloidogenic proteins

  2020cites this paper
• Neuropathological and Biomarker Findings in Parkinson’s Disease and Alzheimer’s Disease: From Protein Aggregates to Synaptic Dysfunction

  2020cites this paper
• Progression of symptoms in Parkinson's disease

  2020cites this paper